Skip to main content

Advertisement

Table 1 Demographic and clinicopathologic characteristics of melanoma patients treated with immunotherapy

From: Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy

Variable Number of patients (n = 71)
Age at diagnosis (years)
  Median (Range) 55 (21–80)
Gender  
  Male 40 (56.3%)
  Female 31 (43.7%)
AJCC stage at diagnosis
  I 5 (7.1%)
  II 26 (36.6%)
  III 40 (56.3%)
Primary TILs  
  Absent 16 (22.6%)
  Present 52 (73.2%)
   Non-brisk 29
   Brisk 23
  Unclassified 3 (4.2%)
Immunotherapy setting a  
  Adjuvant 40 (56.3%)
  At Recurrence 31 (43.7%)
Type of immunotherapy
  Immune biologic 38 (53.5%)
   IFN-α 21
   IL-2, IL-18 4
   GM-CSF 12
   Other 1
  Vaccine 33 (46.5%)
   Dendritic cell 11
   Peptide 22
  1. Abbreviations: AJCC American joint committee on cancer, TILs Tumor-infiltrating lymphocytes, NOS Not otherwise specified.
  2. aPatients who received immunotherapy in both settings (n=6).